Risk Profile Improvements

  • Going Concern (improved) — Cash runway extended from Q1 2026 to Q3 2026, indicating improved near-term liquidity position following receipt of second installment payment and cost reductions.
NASDAQ: MCRB Seres Therapeutics, Inc. 10-Q

Seres extends cash runway to Q3 2026, pauses SER-155 Phase 2, cuts workforce 30%

Filed May 5, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 7, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade MCRB commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.